• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) [Autologous stem cell transplantation for multiple sclerosis : rapid scoping review]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Scottish Health Technologies Group (SHTG) Elective surgery using mesh to repair primary or incisional hernias in adults
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2021     Ontario Health Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment
2021     Scottish Health Technologies Group (SHTG) A Unique Device Identifier (UDI) system for recording, identifying and recalling medical devices
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the QUIDS meta-analysis and prospective cohort study
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evolving profile of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) and surgical aortic valve implantation (SAVR) in Québec, a real-world evaluation from 2013 to 2019]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2021     Health Technology Wales (HTW) Extracorporeal shockwave therapy for the treatment of musculoskeletal conditions
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT
2021     Austrian Institute for Health Technology Assessment (AIHTA) HSR in Oncology: patients with non-small cell lung cancer treated with anti-PD-1/PD-L1 therapy in real-world practice. A pilot project in cooperation with Tirol Kliniken GmbH & KAGes
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Ontario Health Internet-delivered cognitive behavioral therapy for post-traumatic stress disorder and acute stress disorder
2021     Belgian Health Care Knowledge Centre (KCE) Benefits and costs of innovative oncology drugs in Belgium (2004-2017)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia
2021     Health Information and Quality Authority (HIQA) Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021     Ontario Health iStent for Adults With Glaucoma: A Health Technology Assessment
2021     Health Information and Quality Authority (HIQA) Extended interval screening by the Diabetic RetinaScreen Programme in Ireland
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Medical Services Advisory Committee (MSAC) Six genetic tests for the diagnosis of inheritable cardiac conduction disorders
2021     Ontario Health DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines
2021     Health Information and Quality Authority (HIQA) Measures to support people in self-isolation or restriction of movements and the evidence of the effectiveness of such measures
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97]
2021     Ontario Health Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment
2021     Health Information and Quality Authority (HIQA) Potential impact of different serial testing scenarios using rapid antigen detection tests (RADTs) to detect SARS-CoV-2 in meat processing plant workers
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102]
2021     European Network for Health Technology Assessment (EUnetHTA) Convalescent plasma therapy for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114]
2021     Health Information and Quality Authority (HIQA) Potential impact of different testing scenarios and durations of mandatory home quarantine for people travelling to Ireland from non-designated states
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Addendum to Commission A20-113]
2021     European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Public health measures to limit the transmission of SARS-CoV-2 at mass gatherings
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermoablation of the duodenal mucosa in type 2 diabetes - Addendum to commission H20-04]
2021     European Network for Health Technology Assessment (EUnetHTA) Camostat for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021     Malaysian Health Technology Assessment (MaHTAS) HPV vaccine - an update
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) Nafamostat for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) COVID-19 - interventions and health related factors that prevent infection or minimise progression to severe disease
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111]
2021     European Network for Health Technology Assessment (EUnetHTA) Solnatide for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Review of processes in use to inform the expansion of newborn bloodspot screening programmes
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Addendum to Commission A20-106]
2021     European Network for Health Technology Assessment (EUnetHTA) Anakinra for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Economic burden of antimicrobial resistance: an analysis of additional costs associated with resistant infections
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) APN01 for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) Darunavir for the treatment of COVID-19
2021     Norwegian Institute of Public Health (NIPH) [Medpor polyethylene implant in reconstructive ear surgery in patients with microtia: rapid health technology assessment]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) Favipiravir for the treatment of COVID-19
2021     Norwegian Institute of Public Health (NIPH) [Description and quality assessment of guidelines for tonsillectomy in patients with recurrent tonsillitis: mapping review]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irreversible electroporation in chronic bronchitis - Addendum to commission H20-03]
2021     European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Second Addendum to Commission A20-104]
2021     European Network for Health Technology Assessment (EUnetHTA) Interferon (IFN) and Novaferon (NOVA) for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Identification of demand models for estimating the quantities of personal protective equipment (PPE) required for optimal patient care in the context of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-103]
2021     European Network for Health Technology Assessment (EUnetHTA) Gimsilumab for the treatment of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     European Network for Health Technology Assessment (EUnetHTA) Canakinumab for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Rapid antigen testing for screening or surveillance of asymptomatic individuals to limit transmission of SARS-CoV-2
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Addendum to Commission A20-103]
2021     European Network for Health Technology Assessment (EUnetHTA) Casirivimab and imdevimab (REGN-COV2) for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Reduction of the minimum age for the application of mask wearing requirements and recommendations – updated advice
2021     Canary Health Service [Effectiveness of measures to close or restrict occupancy in ceremonial and worship places in the context of the SARS-CoV-2 pandemic]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Addendum to Commission A20-104]
2021     NIHR Public Health Research (PHR) programme A cluster randomised controlled trial of an intervention to improve the mental health support and training available to secondary school teachers the WISE (Wellbeing in Secondary Education) project
2021     European Network for Health Technology Assessment (EUnetHTA) Bamlanivimab for the treatment of COVID-19
2021     NIHR Health Technology Assessment programme Reducing bias in trials from reactions to measurement: the MERIT study including developmental work and expert workshop
2021     Health Sciences Institute in Aragon (IACS) [Congenital ventricular septal defect (VSD) treatment with percutaneous and periventricular insertion devices]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Assessment according to §137h Social Code Book V]
2021     European Network for Health Technology Assessment (EUnetHTA) Baricitinib for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021     Institute for Clinical and Economic Review (ICER) Tezepelumab for severe asthma
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (NSCLC) - Addendum to Commission A20-116]
2021     European Network for Health Technology Assessment (EUnetHTA) Molnupiravir for the treatment of COVID-19
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Training programming for healthcare professionals: How to support patients with chronic diseases to self-manage their health]
2021     Canary Health Service [Effectiveness of measures to close or restrict occupancy in cultural and entertainment places, in the context of the SARS-CoV-2 pandemic]
2021     Institute for Clinical and Economic Review (ICER) Mavacamten for hypertrophic cardiomyopathy: effectiveness and value
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC) - Addendum to Commission A20-118]
2021     European Network for Health Technology Assessment (EUnetHTA) High-dose vitamin D for the treatment of COVID-19
2021     Ontario Health Stance-control knee–ankle–foot orthoses for people with knee instability: a health technology assessment
2021     Institute for Clinical and Economic Review (ICER) Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Center for Drug Evaluation (CDE) [Health economic evaluation of three listed anti-cancer medications]
2021     European Network for Health Technology Assessment (EUnetHTA) Mavrilimumab for the treatment of COVID-19
2021     Austrian Institute for Health Technology Assessment (AIHTA) Stool DNA testing for colorectal cancer (CRC) screening